Events

Reducing the Impact of RSV: What One
FQHC Learned From a Difficult Season

Thursday,

August 27 th, 2026

3:00 - 4:00 PM ET

Speaker

Nichole Van de Putte, MD, FACOG

Maternal Health Director & Chief of Staff
Methodist Hospital Metropolitan
San Antonio, Texas

Director of Obstetrics & Gynecology
CommuniCare
San Antonio, Texas

Reducing the Impact of RSV: What One
FQHC Learned From a Difficult Season

Wednesday,

September 2 nd, 2026

12:00 - 1:00 PM ET

Speaker

Nichole Van de Putte, MD, FACOG

Maternal Health Director & Chief of Staff
Methodist Hospital Metropolitan
San Antonio, Texas

Director of Obstetrics & Gynecology
CommuniCare
San Antonio, Texas

Reducing the Impact of RSV: What One
FQHC Learned From a Difficult Season

Wednesday,

September 9 th, 2026

1:00 - 2:00 PM ET

Speaker

Nichole Van de Putte, MD, FACOG

Maternal Health Director & Chief of Staff
Methodist Hospital Metropolitan
San Antonio, Texas

Director of Obstetrics & Gynecology
CommuniCare
San Antonio, Texas

INDICATION

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

ABRYSVO is a vaccine indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all recipients
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed

Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Please see full Prescribing Information for ABRYSVO.